reports
ANI Pharmaceuticals Inc: 1 director
A director at ANI Pharmaceuticals Inc sold 20,000 shares at 63.440USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen ...
ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP PRINCETON, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) and launched Naproxen Delayed-Release Tablets, USP. ANI’s Naproxen Delayed-Release Tablets is the generic version of the reference listed drug (RLD) EC-Naprosyn®. "We are pleased to announce the first cycle FDA approval and commercialization of Naproxe...
ANI Pharmaceuticals’ CEO Nikhil Lalwani Named EY Entrepreneur Of The Y...
ANI Pharmaceuticals’ CEO Nikhil Lalwani Named EY Entrepreneur Of The Year® 2024 New Jersey Award Winner Recognized for outstanding entrepreneurial leadership, driving impressive growth, and patient impact PRINCETON, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that its Chief Executive Officer, Nikhil Lalwani, has been named an Ernst & Young LLP (EY US) Entrepreneur Of The Year® 2024 New Jersey Award winner. Entrepreneur Of The Year is the preeminent competitive awards program for entrepreneurs and leaders of high...
ANI Pharmaceuticals to Further Expand Rare Disease Business through Ac...
ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences Conference call scheduled for today at 8:30 a.m. ET Strengthens Rare Disease segment as largest driver of future growth, expected to add approximately $105 million in highly durable branded revenueAdds two commercial assets ILUVIEN® and YUTIQ® with significant growth potential, expanding ANI’s foothold in key strategic therapeutic area of ophthalmology Anticipated to drive high single digit to low double digit accretion in adjusted non-GAAP EPS in 2025 and to be substantially accretive there...
ANI Pharmaceuticals to Present at the 2024 Jefferies Global Healthcare...
ANI Pharmaceuticals to Present at the 2024 Jefferies Global Healthcare Conference BAUDETTE, Minn., May 29, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 2024 Jefferies Global Healthcare Conference in New York City as follows: Date:June 5, 2024 Time:4:30 ET Webcast: To schedule a 1x1 meeting with the Company, please contact your Jefferies representative. About ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical co...
ANI Pharmaceuticals Announces the Launch of Kionex® Suspension
ANI Pharmaceuticals Announces the Launch of Kionex® Suspension BAUDETTE, Minn., May 20, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Kionex® (Sodium Polystyrene Sulfonate Suspension USP) for Oral or Rectal use. Kionex® Suspension is the only commercially available therapeutically equivalent to the reference listed drug (RLD) SPS® Suspension for Oral or Rectal use. "The launch of Kionex® Suspension for Oral or Rectal use exemplifies our capability to bring complex generics with limited market competition to our custom...
ANI Pharmaceuticals Reports Record First Quarter 2024 Financial Result...
ANI Pharmaceuticals Reports Record First Quarter 2024 Financial Results and Reiterates 2024 Guidance Generated record quarterly net revenues of $137.4 million, representing year-over-year growth of 28.7%, net income to common shareholders of $17.8 million, and GAAP diluted earnings per share of $0.82Delivered record adjusted non-GAAP EBITDA of $37.6 million, and adjusted non-GAAP diluted earnings per share of $1.21Rare Disease business delivered Q1 net revenues of $36.9 million, representing year-over-year growth of 126.2%Reiterated 2024 guidance of net revenues of $520 million to $542 mill...
ANI Pharmaceuticals to Participate at Two Upcoming Healthcare Conferen...
ANI Pharmaceuticals to Participate at Two Upcoming Healthcare Conferences BAUDETTE, Minn., May 01, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will participate at two upcoming healthcare conferences in New York City as follows: Capital One 1st Annual Biotech/Biopharma Disruptors Event Date:Tuesday, May 14, 2024 Time:12:15pm ET To schedule a 1x1 meeting with management, please contact H.C. Wainwright 2nd Annual BioConnect Conference at N...
ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on...
ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET BAUDETTE, Minn., April 18, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2024 financial results on Friday, May 10, 2024, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows: DateFriday, May 10, 2024 Time8:30 a...
ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension
ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension BAUDETTE, Minn., April 09, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Baclofen Oral Suspension, a generic version of the reference listed drug (RLD) Fleqsuvy®. "The launch of Baclofen Oral Suspension represents another entry for ANI into a rapidly growing limited competition market. We are proud of our ability to recognize the market need and provide our customers with the best suited packing configurations to match their requirements in a tim...
ANI Pharmaceuticals Recognizes Sarcoidosis Awareness Month and Patient...
ANI Pharmaceuticals Recognizes Sarcoidosis Awareness Month and Patients Living with Sarcoidosis --ANI Pharmaceuticals is proud to support Sarcoidosis disease awareness-- BAUDETTE, Minn., April 04, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq : ANIP) is proud to support the Foundation for Sarcoidosis Research’s (FSR) commitment to sarcoidosis patients and efforts to increase disease awareness during April’s Sarcoidosis Awareness Month. During the month of April, members of the ANI organization are raising awareness of sarcoidosis by wearing “Say Sarcoi...
ANI Pharmaceuticals to Participate at the Piper Sandler Spring Biophar...
ANI Pharmaceuticals to Participate at the Piper Sandler Spring Biopharma Symposium BAUDETTE, Minn., April 03, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will host investor meetings at the Piper Sandler Spring Biopharma Symposium on Wednesday, April 17, 2024, at the Encore Boston Harbor. To schedule a 1x1 meeting with the Company, please email . About ANI ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company s...
ANI Pharmaceuticals Announces the Launch of Levofloxacin Oral Solution...
ANI Pharmaceuticals Announces the Launch of Levofloxacin Oral Solution, USP BAUDETTE, Minn., March 27, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Levofloxacin Oral Solution, a generic version of the Reference Listed Drug (RLD) Levaquin®. The current annual U.S. market for Levofloxacin Oral Solution is approximately $7.1 million, according to latest estimates from IQVIA/IMS Health, a leading healthcare data and analytics provider. "New product launch execution remains a top priority for ANI as we continue to drive g...
ANI Pharmaceuticals Reports Fourth Quarter and Record Full-Year 2023 F...
ANI Pharmaceuticals Reports Fourth Quarter and Record Full-Year 2023 Financial Results and Provides 2024 Guidance Generated quarterly net revenues of $131.7 million, representing year-over-year growth of 39.7%, net income to common shareholders of $0.7 million, GAAP diluted earnings per share of $0.04Delivered adjusted non-GAAP EBITDA of $30.2 million, and adjusted non-GAAP diluted earnings per share of $1.00Rare Disease business delivered Q4 net revenues of $41.7 million, representing quarter-over-quarter growth of 40.4% and year-over-year growth of 137.3%Generated $119.0 million in cash f...
Moody's revises ANI Pharmaceuticals' outlook to positive; affirms B2 C...
Moody's Investors Service ("Moody's") affirmed ANI Pharmaceuticals, Inc.'s ("ANI") ratings including the B2 Corporate Family Rating (CFR), B2-PD Probability of Default Rating (PDR), and the B2 rating of the senior secured bank credit facilities. ANI's Speculative Grade Liquidity Rating is unchanged ...
ANI Pharmaceuticals to Present at the Leerink Partners Global Biopharm...
ANI Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference BAUDETTE, Minn., Feb. 20, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Leerink Partners Global Biopharma Conference in Miami Beach as follows: Date: Tuesday, March 12, 2024 Time: 2:20 p.m. ET Webcast: To schedule a 1x1 meeting with the Company, please contact your Leerink representative. The live and archived webcast will...
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2023 Finan...
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024, at 8:30 a.m. ET BAUDETTE, Minn., Feb. 07, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2023 financial results on Thursday, February 29, 2024, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as foll...
ANI Pharmaceuticals to Participate at the Guggenheim Healthcare Talks ...
ANI Pharmaceuticals to Participate at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference BAUDETTE, Minn., Jan. 29, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference in New York City as follows: Date: Thursday, February 8, 2024 Time: 10:30 a.m. ET Webcast: To schedule a 1x1 meeting with the Company, please email: The live and archived webcast will be acce...
ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Re...
ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP BAUDETTE, Minn., Jan. 23, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Pentoxifylline Extended-Release (ER) Tablets, USP 400mg. ANI’s Pentoxifylline ER Tablets are the generic version of the Reference Listed Drug (RLD) Trental®. The current annual U.S. market for Pentoxifylline ER Tablets is approximately $19.7 million, according to latest estimates from IQVIA/IMS Health, a leading healthcare data and analytics provider. “We are...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.